Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- CheckyesterdayChange DetectedRemoved a general notice about government funding and NIH Clinical Center operations from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedNo additions or deletions were detected; page content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check37 days agoChange DetectedUpdate of geographic region labels to Auvergne-Rhône-Alpes with city-level detail for Lyon (69008); replaces Rhône-Alpes references.SummaryDifference4%

- Check45 days agoChange Detected- Updated medical terminology from 'Medullary thyroid gland carcinoma' to 'Medullary thyroid carcinoma' and bumped version to v3.2.0.SummaryDifference0.1%

- Check46 days agoChange DetectedTerminology updated from “Medullary thyroid gland carcinoma” to “Medullary thyroid carcinoma” with a new version tag v3.1.0.SummaryDifference0.1%

- Check60 days agoChange DetectedUpdated the page from Revision v3.0.1 to v3.0.2; removed the 'Back to Top' element.SummaryDifference0.1%

Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.